EA
CLDX icon

Ellsworth Advisors’s Celldex Therapeutics CLDX Stock Holding History

Ellsworth Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$958K Buy
+29,572
New +$1.13M 0.15% 119

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Apella Capital
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
OMC
Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Ellsworth Advisors's CLDX Position: Q3 2026 in Review

Ellsworth Advisors opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 29,572 shares worth $958K. The stake represents 0.15% of the portfolio and ranks #119 among its holdings.

15 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Ellsworth Advisors held 29,572 shares of Celldex Therapeutics worth $958K as of Q3 2026.
  • Celldex Therapeutics was a new Ellsworth Advisors position in Q3 2026.
  • Celldex Therapeutics made up 0.15% of Ellsworth Advisors's portfolio in Q3 2026, its #119 holding.
  • 15 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.